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The nervous system is highly sensitive to experience during early postnatal life, but this phase of heightened plasticity decreases
with age. Recent studies have demonstrated that developmental-like plasticity can be reactivated in the visual cortex of adult
animals through environmental or pharmacological manipulations. These findings provide a unique opportunity to study the
cellular and molecular mechanisms of adult plasticity. Here we used the monocular deprivation paradigm to investigate large-
scale gene expression patterns underlying the reinstatement of plasticity produced by fluoxetine in the adult rat visual cortex.
We found changes, confirmed with RT-PCRs, in gene expression in different biological themes, such as chromatin structure
remodelling, transcription factors, molecules involved in synaptic plasticity, extracellular matrix, and excitatory and inhibitory
neurotransmission. Our findings reveal a key role for several molecules such as the metalloproteases Mmp2 and Mmp9 or the
glycoprotein Reelin and open up new insights into the mechanisms underlying the reopening of the critical periods in the adult
brain.
1. Introduction
Use-dependent plasticity shapes neuronal networks within
sensory systems during early life to optimally represent
sensory stimuli [1]. Experience-dependent organization of
eye-specific inputs is amajormechanismwhereby refinement
of synaptic connectivity is achieved in the developing visual
system [2–4]. Monocular deprivation during development
leads to a loss of cortical connectivity of the deprived eye
resulting in a shift of the ocular dominance in the visual
cortex, which will become permanent if the MD persists
to adulthood [5, 6]. Although neuronal plasticity of the
developing brain gradually decreases with age [7], recent
findings suggest that it can be reactivated in the adult visual
cortex [8] and other regions, such as the amygdala [9]. A
variety of experimental manipulations, including enzymatic
treatments [10, 11], environmental enrichment [12–15], food
restriction [16], genetic manipulations [17, 18], and other
manipulations, promote this kind of plasticity [19–21].
Although themechanisms behind the adult induced plas-
ticity are still unclear, we are beginning to understand the key
factors involved. For example, the developmental maturation
of neuronal inhibition, mainly through the parvalbumin
containing interneurons [22, 23], is known to be involved
in both the opening and the closure of the critical period
[20]. Several extracellular matrix components, such as PSA-
NCAM or the perineuronal nets, have been shown to play
a role in the maturation of the inhibitory circuitries and
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Figure 1: Experimental design and Venn diagram. (a) Schematic graph showing the different animal groups and experimental conditions
conducted. (b) Venn diagram showing the number of genes differentially expressed when comparing the effects of monocular deprivation
(BV-Sal versus MD-Sal), the effects of fluoxetine in animals with binocular vision (BV-Sal versus BV-Flx), and those of fluoxetine in animals
with monocular deprivation (MD-Sal versus MD-Flx).
experimental manipulations removing these extracellular
matrix components, can trigger an early closure [24] or a
reopening of the critical period, respectively [11]. Similarly, a
variety of other molecules, such as transcription factors [25]
or proteins involved in chromatin structure remodeling [26],
are also key factors in regulating the closure and reopening of
the critical period.
The main pharmacological approaches to experimentally
regulate critical period plasticity in the adulthood are those
affecting the action of ascending projection systems, such
as the serotoninergic or cholinergic systems [21, 27–29]. In
this line, we have investigated the plastic effects of antide-
pressants, such as fluoxetine, that modulate serotoninergic
transmission, and we have shown that these drugs, in a long-
term treatment, are able to trigger critical period plasticity in
the adult brain [8], through an early epigenetic modification
that regulates gene expression [29].
Here, we have used fluoxetine in combination with an
experience-dependent paradigm of visual deprivation, to
analyze the large-scale gene expression patterns, to under-
stand the temporal-dependent changes that allow the reopen-
ing of the critical periods in the adult brain.
2. Experimental Procedures
2.1. Animal Treatment, Fluoxetine Administration, and Surgi-
cal Procedures. A total amount of 32 Long-Evans hooded rats
were used in this study, equally distributed in 4 experimental
groups (𝑛 = 8 animals per group), as explained later
(Figure 1(a)). Animals were group-housed under standard
conditions with food and water ad libitum in plexiglas cages
(40 × 30 × 20 cm) and kept in a 12 : 12 light/dark cycle.
Adult rats at the postnatal day 70 (P70) were systemically
treatedwith fluoxetine (fluoxetine-hydrochloride, 0.2mg/mL
drinking water) for 23 days. Control animals were housed
under the same standard conditions drinking tap water.
Three weeks after the beginning of the fluoxetine treat-
ment, rats were anaesthetized with avertin (1mL/100 g) and
mounted on a stereotaxic apparatus to perform the eye-
lid suture for monocular deprivation (MD). Eyelids were
inspected daily until complete cicatrisation; subjects with
even minimal spontaneous reopening were excluded. Great
care was taken during the first days after MD to prevent
inflammation or infection of the deprived eye through topical
application of antibiotic and cortisone.
2.2. DNA Microarrays and Data Analysis. Two days after
MD, the binocular region of the primary visual cortex was
dissected. For all microarray experiments, total RNA was
purified using RNA extraction kit (Macherey Nagel), and
Amino Allyl cRNA labeling Kit (Ambion) was used to
label cRNA according to manufacturer’s standard protocols.
Agilent Whole Rat Genome Microarray Kits (4 × 44K) were
hybridized following provided protocols.
Images fromhybridizedmicroarrays were segmented and
the median intensity of each spot was estimated by the
software GenePix v.5.0 (axon). Data was imported into the
software (http://cran.r-project.org/) and preprocessed by the
bioconductor package limma. The statistical analysis used
was a linear model followed by 𝑡-test for finding the differ-
entially expressed genes. In order to increase the reliability of
the statistical analysis, we only considered significant those
genes with a 𝑃 value less than 0.01. In addition, we also
increase the reliability of the analysis through validation of
the results using multiple RT-PCRs. Lists of significant genes
were screened by the DAVID 6.7 annotation tools in order
to find overrepresented biological themes. Default DAVID
parameters were used.
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2.3. Real-Time PCR. RNA purification was performed accor-
ding to the standard Trizol procedure (Invitrogen). Purified
RNA was treated with DNAse (Fermentas) and cDNA was
synthesised from 1 𝜇g of RNA (Invitrogen). Real-time PCR
was carried out to determine relative enrichment in the
samples using the Sybr Green method according to the
manufacturer instructions (SYBRGreen Imaster, Light cycler
480, Roche Diagnostics). The comparative Ct method [30]
was used to determine the normalized changes of the target
gene relative to a calibrator reference; in particular, values
were normalized toGAPDH levels. As calibrator referencewe
referred to Ct from water-treated animal samples.
3. Results
3.1. DNA Microarrays. Previous studies have shown that 7
days period of monocular deprivation in fluoxetine-treated
adult rats is sufficient to bring about a change in the ocular
dominance. To reveal early transcriptional changes that
precede and underlie the functional change, we analysed
gene expression, using DNA microarrays, at two days after
MD. Microarray analysis revealed only relatively few genes
that were significantly regulated by either FLX (𝑛 = 197,
see Supplementary Table S1 in the Supplementary Material
available online at http://dx.doi.org/10.1155/2013/605079) or
MD alone (𝑛 = 239, Table S2), treatments that themselves do
not produce any changes in the ocular dominance plasticity.
However, the combination of FLX and MD, the treatment
that promotes changes in ocular dominance, altered the
expression of a significantly larger number of genes (𝑛 =
1603, Table S3, Figure 1(b)). Notably 1237 out of 1603 (77%)
of the genes in the group receiving both MD and FLX
were downregulated, whereas in the groups receiving either
MD or FLX, 111 out of 239 and 88 out of 197 genes were
downregulated, respectively, comprising of roughly 50%of all
the regulated genes.Hence, the combination of the treatments
apparently has two major effects on gene expression; first, it
increases the number of regulated genes when compared to
the single treatments, and second, it has a striking effect on
downregulating most of the genes, indicating that silencing
of genes normally expressed during basal conditions is likely
involved in the triggering of plasticity of the adult brain.
The representation of biological themes was screened
using Fisher’s Exact test on the lists of differentially expressed
genes in each comparison. Chronic fluoxetine treatment
induced a regulation of genes related to chromatin remod-
elling, nervous system development, and plasticity, as well
as regulation of gene expression and transcription in the
binocular visual cortex (Table S4).
MD altered the expression of a significant number of
genes related to cell differentiation, cell plasticity, and neuro-
genesis. Several genes of the ion homeostasis and regulation
of transcription were also found overexpressed (Table S5).
The combination of MD and fluoxetine treatment down-
regulated the majority of the differentially expressed genes,
altering the expression of genes represented in a variety of
functional processes, including genes related to neuronal
development, plasticity, and apoptosis. In addition, genes
involved in the synaptic transmission, ion and intracellular
calcium homeostasis, and vesicular secretion were found dif-
ferentially expressed. Blood circulation and lipid metabolism
were among the most significantly overrepresented families
(Table S6).
3.2. RT-PCR. To provide validation of the microarray data,
we next examined single patterns of gene expression by
means of real-time PCR, in the same experimental groups
and using the same experimental paradigm (Figure 1(a)). In
particular, we focused our attention on genes whose expres-
sion may alter molecular and cellular processes involved in
the closure of the critical period for visual cortex plasticity,
such as the balance of inhibitory and excitatory transmission
[22, 31, 32], transcription factors regulating gene expression
[25], extracellular matrix remodeling [11], myelination [33],
and chromatin structure remodeling [26, 29], as well as
genes involved in processes of synaptic plasticity, neuronal
differentiation, and outgrowth (see Table 1).
3.2.1. Inhibitory Neurotransmission. We observed that fluox-
etine produced a significant increase in the expression of
genes involved in inhibitory neurotransmission when com-
paring both animals with binocular vision and animals with
monocular deprivation with their respective controls (BV-
Sal versus BV-Flx and MD-Sal versus MD-Flx; Figure 2(a)).
Specifically, in animals with binocular vision, we found
an increased expression of the vesicular GABA transporter
(VGAT; 60% increased expression; 𝑃 = 0.001), while in
rats with monocular deprivation together with fluoxetine
treatment, we observed an increase in the expression of
GABRA4 (30% increased expression; 𝑃 = 0.02).
3.2.2. Excitatory Neurotransmission. We did not observe
many changes in the composition of NMDA receptor sub-
units in either of the experimental groups (see Figure 2(b)
and Table 1). The only significant change we found was a
decrease in the expression of the NR2A subunit (NMDA-2A;
20% decreased expression; 𝑃 = 0.04) in the animals with
monocular deprivation treated with fluoxetine.
3.2.3. Transcription Factors. We detected increases in the
gene expression of transcription factors in the animals with
binocular vision treated with fluoxetine (Figure 2(c)). In
particular, NFKB1 and DLX1 increased their expression (50%
and 30% increased expression, resp.;𝑃 = 0.04 and 0.03, resp.).
However, in those animals with monocular deprivation,
fluoxetine treatment produced a decrease in the expression
of transcription factors, such as EGR-2 (𝑃 = 0.04).
3.2.4. Synaptic Plasticity. The expression of Reelin, transcript
that encodes a glycoprotein that mediates synaptic plasticity
at hippocampal level [34], was significantly increased in MD
animals treated with fluoxetine (Figure 2(d); 40% increased
expression; 𝑃 = 0.001). The expression of additional
transcripts that encode proteins involved in neuronal dif-
ferentiation and outgrowth processes as well as synaptic
plasticity increased in both groups. In animals with binocular
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Table 1: RT-PCR analysis.
Gene symbol Entrez gene ID Treatment comparison 𝑃 value Fold change
KCNQ3 29682 BV-Sal versus BV-Flx 0.01 1.3
KCNQ3 29682 MD-Sal versus MD-Flx 0.02 1.3
MMP9 81687 BV-Sal versus BV-Flx 0.13 1.1
MMP9 81687 MD-Sal versus MD-Flx 0.01 1.5
VGAT 83612 BV-Sal versus BV-Flx 0.001 1.6
VGAT 83612 MD-Sal versus MD-Flx 0.72 1.1
DLX1 296500 BV-Sal versus BV-Flx 0.03 1.3
DLX1 296500 MD-Sal versus MD-Flx 0.25 1.0
EGR2 114090 BV-Sal versus BV-Flx 0.86 1.1
EGR2 114090 MD-Sal versus MD-Flx 0.04 0.7
EGR4 25129 BV-Sal versus BV-Flx 0.29 1.2
EGR4 25129 MD-Sal versus MD-Flx 0.38 0.9
mGluR1 24414 BV-Sal versus BV-Flx 0.47 1.0
mGluR1 24414 MD-Sal versus MD-Flx 0.98 1.1
HDAC3 15183 BV-Sal versus BV-Flx 0.02 1.3
HDAC3 15183 MD-Sal versus MD-Flx 0.92 1.1
KCNV1 60326 BV-Sal versus BV-Flx 0.02 1.2
KCNV1 60326 MD-Sal versus MD-Flx 0.10 1.2
NFKB1 81736 BV-Sal versus BV-Flx 0.04 1.5
NFKB1 81736 MD-Sal versus MD-Flx 0.52 1.0
CLCN3 84360 BV-Sal versus BV-Flx 0.04 1.2
CLCN3 84360 MD-Sal versus MD-Flx 0.01 1.5
NR1 24408 BV-Sal versus BV-Flx 0.45 0.9
NR1 24408 MD-Sal versus MD-Flx 0.43 1.1
NR2A 14811 BV-Sal versus BV-Flx 0.63 1.1
NR2A 14811 MD-Sal versus MD-Flx 0.04 0.8
NR2B 24410 BV-Sal versus BV-Flx 0.51 1.1
NR2B 24410 MD-Sal versus MD-Flx 0.07 0.8
GABRA1 29705 BV-Sal versus BV-Flx 0.34 1.1
GABRA1 29705 MD-Sal versus MD-Flx 0.27 0.9
GABRA4 140675 BV-Sal versus BV-Flx 0.29 1.1
GABRA4 140675 MD-Sal versus MD-Flx 0.02 1.3
Reelin 24718 BV-Sal versus BV-Flx 0.15 1.2
Reelin 24718 MD-Sal versus MD-Flx 0.001 1.4
MMP2 17390 BV-Sal versus BV-Flx 0.02 0.5
MMP2 17390 MD-Sal versus MD-Flx 0.01 1.6
MBP 24547 BV-Sal versus BV-Flx 0.01 0.6
MBP 24547 MD-Sal versus MD-Flx 0.01 0.6
vision, fluoxetine promoted an increase in the expression
of CLCN3 (20% increased), KCNV1 (20% increased), and
KCNQ3 (30% increased), which encode ion channels that
mediate chloride and potassium conductance (𝑃 < 0.05), and
in animals with monocular deprivation fluoxetine produced
also an increase in the expression of CLCN3 (50% increased
expression; 𝑃 = 0.01).
3.2.5. Extracellular Matrix. The expression of MMP2 and
MMP9 was markedly changed between animals treated
with fluoxetine and with binocular vision and those with
monocular deprivation (Figure 2(e)). MMP2 and MMP9
encode for proteolytic enzymes that degrade extracellular
matrix components [35–37] and play a key role in mediating
synaptic plasticity at the level of the hippocampus [38, 39]. In
particular, MMP2 gene expression was decreased in animals
treated with fluoxetine alone (50% decrease; 𝑃 = 0.02),
while animals with combined monocular deprivation and
chronic fluoxetine treatment had an increased expression of
both MMP2 (60% increased; 𝑃 = 0.01) and MMP9 (50%
increased; 𝑃 = 0.01).
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Figure 2: Effects of fluoxetine in the expression of genes involved in critical period plasticity. qRT-PCR mRNA fold change comparison
between the effects of fluoxetine in rats with binocular vision and monocular deprivation. Statistical data is grouped by binocular vision or
monocular deprivation, and in each part the position of the line represents the fold change of the fluoxetine treated group (coloured line)
with respect to the saline treated group (grey dashed line) (BV-Sal versus BV-Flx and MD-Sal versus MD-Flx, resp.). All gene expression was
normalized using GAPDH as a control gene.
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3.2.6. Chromatin Remodeling and Myelination. Changes in
the expression of transcripts that encode an enzyme that reg-
ulate chromatin susceptibility to transcription were detected
in animals with binocular vision after chronic fluoxetine
treatment. In particular, we found that Hdac3 expression was
enhanced (Figure 2(f); 30% increased𝑃 = 0.02). On the other
hand, the expression of MBP, which encodes a basic protein
of myelin, a repressive factor for visual cortex plasticity [33],
was significantly reduced by fluoxetine treatment in animals
with both binocular vision (40% decreased; 𝑃 = 0.01) and
monocular deprivation (40% decreased; 𝑃 = 0.001).
4. Discussion
This study provides a large-scale analysis of changes in
patterns of gene expression associated with the reopening
of the critical period of plasticity in the adult visual system
induced by the combination of fluoxetine treatment and
monocular deprivation. Our findings suggest a scenario
where an enhanced serotoninergic transmission induced
by long-term fluoxetine treatment induces a shift of the
inhibitory-excitatory balance [8, 29], which in turn promotes
an alteration in the expression of genes involved in different
biological themes that may underlie the functional modifica-
tions in the adult visual cortex related with the reopening of
the critical period plasticity [40].
Our results reveal that the process of plasticity reactiva-
tion in adulthood involves both (i) a transient activation of
neural mechanisms normally present during early stages of
brain development and (ii) a removal of molecular factors
that inhibit plasticity in adulthood [19]. Gene expression
patterns involved in processes of synaptic plasticity, neuronal
differentiation, and outgrowth were, indeed, differentially
regulated by chronic fluoxetine treatment.
The increased expression of Reelin may represent an
example of the first mechanism. Reelin is an extracellular
glycoprotein involved in the migration and correct devel-
opment of the cerebral cortex [41, 42]. Reelin is highly
expressed by Cajal-Retzius neurons during development, but
its expression is limited to a subpopulation of interneurons
during the adulthood [43, 44]. Although the function of
Reelin in adult neurons remains unclear, its overexpression
has been shown to enhance plasticity and learning, affecting
presynaptic transmission [34, 45]. Our results demonstrate
an upregulation of Reelin after chronic fluoxetine treatment,
suggesting that the overexpression of molecules involved
in the juvenile plasticity plays an important role in the
reopening of the critical periods during the adulthood.
The proteolytic enzyme Mmp2, on the other hand, may
drive mechanisms of synaptic plasticity by degrading extra-
cellular matrix components that are inhibitory for plasticity,
as observed in the adult hippocampus [39]. Increase ofMmp2
expression, indeed, was paralleled by a decrease of Mbp: a
basic component of myelin, which is a repressive factor for
visual cortex plasticity [33]. Our analysis of gene expression
points towards a downregulation ofMbp following long-term
antidepressant treatment, supporting the hypothesis that the
removal of factors that are inhibitory for plasticity may pro-
vide a permissive environment for structural and functional
changes of neuronal circuitries in the adult nervous system
[19].
Chronic fluoxetine administration has been shown to
promote structural changes in both excitatory [46, 47] and
inhibitory circuits [48–50]. Although there is evidence that
long-term fluoxetine administration promotes a reduction
of GABA-mediated inhibition in adult visual cortical cir-
cuitries [8, 29], a compensatory mechanism might explain
the increase in the expression of VGAT or GABRA4 that
we observe in our experiment. These results are also in
agreement with previous studies, in which fluoxetine treat-
ment in combination with monocular deprivation produces
an increase in the elongation of the tips of interneuronal
dendrites [50], supporting the idea that inhibitory neuro-
transmission plays a key role in the reopening of the critical
periods [20, 22, 23]. Similarly, the change of NMDA receptor
subunit composition, evidenced by the decrease in NMDA-
2A gene expression following antidepressant treatment, is
particularly interesting in this respect. The expression of
the NR2A subunit has been correlated with a progressive
decrease of NMDA receptor currents during development
[51, 52]. This raises the possibility that a decrement of the
NR2A/B ratio may increase NMDA receptors sensitivity
thus causing the strengthening of synapses required for the
potentiation of the nondeprived input [53].
Another highly significant notion that emerges from our
data is that the changes promoted by the combination of
fluoxetine withmonocular deprivation, regarding the expres-
sion of transcription factors and proteins of the extracellular
matrix, are opposed to those promoted by fluoxetine alone.
This indicates that these molecules might be underlying the
structural plasticity changes driven by monocular depriva-
tion to produce the shift in the ocular dominance and its
consolidation in the visual system [54].
Our findings support the hypothesis that the therapeutic
effect of antidepressant drugs is dependent on changes in
neuronal plasticity [55, 56]. Importantly, these results open
up new insights into the understanding of the mechanisms
underlying the reopening of the critical period in the adult
brain, by providing the basis of gene expression patterns for
a visual deprivation paradigm that demonstrates the ability
of the nervous system to translate environmental stimuli into
structural and functional changes of neural circuitries.
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